Histone Deacetylase 6 Inhibitor JS28 Prevents Pathological Gene Expression in Cardiac Myocytes

BACKGROUND: Epigenetic modulators have been proposed as promising new drug targets to treat adverse remodeling in heart failure. Here, we evaluated the potential of 4 epigenetic drugs, including the recently developed histone deacetylase 6 (HDAC6) inhibitor JS28, to prevent endothelin‐1 induced path...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Vivien, Fleischmann, Bernd K., Jung, Manfred, Hein, Lutz, Lother, Achim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238633/
https://www.ncbi.nlm.nih.gov/pubmed/35699165
http://dx.doi.org/10.1161/JAHA.122.025857

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9238633/
https://www.ncbi.nlm.nih.gov/pubmed/35699165
http://dx.doi.org/10.1161/JAHA.122.025857

Ejemplares similares